Clinical Medicine & Research最新文献

{"title":"Anthropometric Measures for the Prognosis of Obstructive Sleep Apnea in Obese.","authors":"Laura Souza Lagares, Ramon Souza Lino, Eric Simas Bomfim, Felipe Almeida Santos, Ciro Oliveira Queiroz, Lélia Lessa Pinto, Luiz Alberto Bastos Almeida, Clarcson Plácido Santos","doi":"10.3121/cmr.2022.1679","DOIUrl":"10.3121/cmr.2022.1679","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to identify, among the different anthropometric indicators, the one that shows higher discriminatory power for the prognosis of Obstructive Sleep Apnea Syndrome (OSAS).</p><p><strong>Design: </strong>Observational cross-sectional study PARTICIPANTS: Obese individuals elective to bariatric surgery METHODS: A study based on data of 758 patients aged ≥ 21 years old, of both sexes, in the pre-operatory stage of the surgical procedure of gastric bypass. Obstructive sleep apnea and obstructive sleep hypopnea were evaluated and classified through the apnea-hypopnea index, which was obtained through the examination of polysomnography. Variables were divided into two groups: individuals with and without OSAS. As predictors, measures of body mass index (BMI), neck circumference (NC), and waist circumference (WC) were used.</p><p><strong>Results: </strong>The area under the ROC curve was used to check the sensitivity and specificity. All evaluated anthropometric indicators showed statistical significance. WC: area of 0.62 (CI 95%: 0.58 - 0.67), NC: area of 0,68 (CI 95%: 0.64 - 0.72) and BMI: area of 0.58 (CI 95%: 0.54 - 0.63).</p><p><strong>Conclusion: </strong>The investigated anthropometric indicators performed as good predictors of OSAS. However, NC seems to be the best anthropometric indicator for the prognosis of OSAS in obese individuals when compared to BMI and WC.</p>","PeriodicalId":47429,"journal":{"name":"Clinical Medicine & Research","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544195/pdf/0200147.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10460080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended Tourniquet Times and the Impact on Wound Healing in Foot Surgery","authors":"Callum Robertson, V. Wilson, R. Meek, R. Carter","doi":"10.3121/cmr.2022/1668","DOIUrl":"https://doi.org/10.3121/cmr.2022/1668","url":null,"abstract":"Objective: The aim of this study was to compare the effect of tourniquet time less than or in excess of 120 minutes on foot surgery wound healing. Null hypothesis: A tourniquet time of over 120 minutes will not affect wound healing in foot surgery. Design, Setting, Participants and Method: A retrospective comparative cohort analysis was performed on 96 patients undergoing complex hindfoot surgery in a large central teaching hospital. Fifty-five patients receiving tourniquet pressure for >120 minutes and 41 receiving <120 minutes of tourniquet pressure were identified from electronic case records. The primary outcome was surgical wound healing. Secondary outcomes were discharge date and complication rate. Results: There was no significant difference in reported time for wounds to heal in the <120-minute or >120-minute cohort. There were no other significant differences in secondary clinical outcomes and no significant variations in patient demographics. Conclusion: This study suggests that tourniquet times from 2 to 3 hours in foot and ankle surgery with pressures up to 300 mmHg are not associated with a significant effect on wound healing.","PeriodicalId":47429,"journal":{"name":"Clinical Medicine & Research","volume":"62 1","pages":"141 - 146"},"PeriodicalIF":1.4,"publicationDate":"2022-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88353309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meperidine-Ketorolac Combination Provides Better Analgesia than Meperidine Alone in Postoperative Patients.","authors":"Nelly N Umukoro, Shola S Jamgbadi, Erdoo S Isamade","doi":"10.3121/cmr.2022.1628","DOIUrl":"10.3121/cmr.2022.1628","url":null,"abstract":"<p><strong>Background: </strong>Our study objective was to assess if multi-modal analgesia with meperidine-ketorolac combination provides superior analgesia or reduces opioid requirement following surgery compared to Meperidine alone.</p><p><strong>Design: </strong>Double-blind randomized controlled trial.</p><p><strong>Setting: </strong>Postoperative pain control in orthopedic ward after spinal anesthesia.</p><p><strong>Patients: </strong>American Society of Anesthesiology (ASA) risk I or II (ASA I/II) patients who had lower limb implant surgery (88) at our center from September 2014 to July 2015.</p><p><strong>Interventions: </strong>Patients were randomly assigned to receive either 1 mg/kg of intravenous (IV) meperidine and 30 mg of IV ketorolac (treatment group) or 1 mg/kg of IV meperidine (control group) post-surgery, administered every hour for the first 6 hours during the first 24 hours post-surgery. In addition, patients received intravenous meperidine on an 'as needed basis' during the first 24 hours of the postoperative period.</p><p><strong>Measurements: </strong>Outcomes were time-to-first analgesia request postoperatively; cumulative opioid dose in first 24 hours post-surgery; frequency of side effects; and patient satisfaction with pain relief using a Likert scale. Numerical rating scale (NRS) pain scores hourly for the first 6 hours, then the 8th, 12th, 16th, 18th and 24th hour post-surgery were assessed.</p><p><strong>Results: </strong>There was a significant delay in time of first request for analgesia (460 min vs 225 min; <i>P</i>=0.03) and a reduction in opioid consumption in 24 hours (299 mg vs 325 mg; <i>P</i>=0.01) in the meperidine/ketorolac group compared with the meperidine alone group which were both statistically significant. Patient satisfaction with pain relief was better in the treatment group (<i>P</i>=0.01). Additionally, there were fewer side effects in the treatment group than in the control group but this was not statistically significant.</p><p><strong>Conclusions: </strong>Adding ketorolac to meperidine reduced postoperative pain, reduced patient daily opioid requirement, increased patient satisfaction with pain relief, without increasing the frequency of side effects. Therefore, IV ketorolac addition to opioids may be a reasonable option in multimodal analgesic protocol.</p>","PeriodicalId":47429,"journal":{"name":"Clinical Medicine & Research","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544193/pdf/0200133.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10455929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effectiveness of Oral Immunotherapy in Patients with Sesame Anaphylaxis using Omalizumab.","authors":"Fereshteh Salari, Mohammad Hassan Bemanian, Morteza Fallahpour, Seyed Alireza Mahdaviani, Sima Shokri, Majid Khoshmirsafa, Farhad Seif, Mohammad Nabavi, Saba Arshi","doi":"10.3121/cmr.2022.1730","DOIUrl":"10.3121/cmr.2022.1730","url":null,"abstract":"<p><strong>Objective: </strong>Sesame allergy is the most prevalent allergy to seeds. Oral immunotherapy (OIT) is defined as continuous consumption of an allergen at special doses and time. Omalizumab (Anti-IgE) increases tolerance to allergens used in OIT. This study evaluated the effectiveness of a new sesame OIT protocol in patients with sesame anaphylaxis in combination with omalizumab.</p><p><strong>Methods: </strong>In this prospective open-label interventional trial study, 11 patients with a history of sesame anaphylaxis were enrolled after confirmation by oral food challenge (OFC) test. At baseline, skin prick test (SPT) and skin prick to prick (SPP) test were performed. Serum sesame-specific IgE (sIgE) levels were measured. The maintenance phase was continued at home with daily sesame intake for 4 months. At the end of month 4, the OFC and above-mentioned tests were repeated to evaluate the treatment effectiveness.</p><p><strong>Results: </strong>All 11 patients who underwent sesame OIT after 4 months could tolerate a dietary challenge of 22 ml tahini (natural sesame seed, equal to 5,000 mg of sesame protein and higher) and the average of wheal diameter in the SPT and SPP tests significantly decreased after desensitization.</p><p><strong>Conclusion: </strong>This OIT protocol may be a promising desensitization strategy for patients with sesame anaphylaxis. Also, omalizumab appears to have reduced the severity of reactions.</p>","PeriodicalId":47429,"journal":{"name":"Clinical Medicine & Research","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544196/pdf/0200125.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10455931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cinema's Terrifying Realities: Pandemics, Zombification, and SARS-COV-2.","authors":"Dennis Henkel, Eelco F M Wijdicks","doi":"10.3121/cmr.2022.1742","DOIUrl":"10.3121/cmr.2022.1742","url":null,"abstract":"<p><p>Contagion is a function of the properties of the pathogen, social interactions, and personal relationships in the society it attacks. Filmmakers in the horror genre were inspired by the idea of rabies as a virus that could mutate into something more dangerous. Fictional epidemics of scavenging undead were often attributed to encephalitis caused by rabies or a mutated rabies virus. During the early months of the SARS-COV-2 pandemic, there was a spike in streaming of <i>Contagion</i> that portrays a viral infectious disease modeled after a bat virus that spreads at an alarming rate, unleashing a global public panic and a clueless governmental response. We wanted to trace how filmmakers used rabies pathology as source material for their plots. We searched internet film databases and reviewed fictional films that utilized this plot device. Many dystopic, rabies-induced pandemic scenarios - mostly from the zombie genre - reveal parallels to the COVID-19 pandemic. Many zombie films, despite their absurd premise, anticipated the realities of future pandemics.</p>","PeriodicalId":47429,"journal":{"name":"Clinical Medicine & Research","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544194/pdf/0200121.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10455930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Vasoconstrictor-Induced Non-Occlusive Mesenteric Ischemia of Colon: A Systematic Review.","authors":"Umer Farooq, Daniel Alcantar, Zahoor Ahmed, Ayokunle T Abegunde","doi":"10.3121/cmr.2022.1726","DOIUrl":"10.3121/cmr.2022.1726","url":null,"abstract":"<p><strong>Background: </strong>Nonocclusive mesenteric ischemia (NOMI) is due to mesenteric arterial hypoperfusion from several causes, such as hypovolemia, heart failure, shock, vasoconstrictors, and severe liver or renal disease. Vasoconstrictor-induced NOMI is usually iatrogenic or associated with cocaine use.</p><p><strong>Objectives: </strong>Anecdotal reports suggest that cocaine-induced NOMI has the highest mortality among vasoconstrictors. This review aims to compare the outcomes of colonic NOMI secondary to cocaine versus other vasoconstrictors.</p><p><strong>Methods: </strong>We conducted a systematic search of MEDLINE from inception through October 2016 to find articles on colonic NOMI. The study's primary outcomes were mortality and hospital length of stay (LOS), while secondary outcomes included the need for surgery. We reported descriptive statistics as percentages or median and interquartile range (IQR). We compared continuous data with the Mann-Whitney test and categorical data with Fisher's exact test; <i>P</i> < 0.05 was statistically significant.</p><p><strong>Results: </strong>Of the 59 studies, 20 case reports and 3 case series (n= 27 patients) met the inclusion criteria. There was no difference in mortality between cocaine-induced NOMI and non-cocaine NOMI (<i>P</i>=1.0). There were statistically significant differences between cocaine and non-cocaine vasoconstrictor-induced colonic NOMI regarding surgery (60% vs. 5.8%, <i>P</i>=0.03) and median LOS (7 days vs. 4 days, <i>P</i>=0.04).</p><p><strong>Conclusion: </strong>Cocaine-induced NOMI and non-cocaine NOMI both appear to have a relatively high but similar mortality rate, but the former is associated with increased requirement for surgery and LOS; prompt recognition of this clinical entity is required to improve outcomes.</p>","PeriodicalId":47429,"journal":{"name":"Clinical Medicine & Research","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544191/pdf/0200164.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10456210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complications Associated with Polydek Sutures Used in Eyelid Lateral Tarsal Strip Procedures.","authors":"Lin Chen,&nbsp;Robert B Penne","doi":"10.3121/cmr.2021.1661","DOIUrl":"https://doi.org/10.3121/cmr.2021.1661","url":null,"abstract":"<p><p>Suture-related complications can occur in response to a patient's immune system activation regardless of surgical site. However, there is minimal literature describing complications related to commonly used Polydek sutures. We report the diagnosis, treatment, and follow up of four cases of Polydek suture-related complications post-eyelid lateral tarsal strip procedures, including an early wound healing problem/infection and later granuloma formation and/or suture extrusion that only resolved after removal of the Polydek suture or granuloma tissue. Use of non-Polydek sutures may reduce the likelihood for post-operative suture complications.</p>","PeriodicalId":47429,"journal":{"name":"Clinical Medicine & Research","volume":"20 2","pages":"107-110"},"PeriodicalIF":1.4,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242731/pdf/0200107.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39794904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surveillance of Fluoroquinolone Resistance in Wisconsin: Geographic Variation and Impact of Revised CLSI Breakpoints.","authors":"Giovanna Lazzerini,&nbsp;Stephen C Lavey,&nbsp;Barry C Fox,&nbsp;Erik Munson","doi":"10.3121/cmr.2021.1718","DOIUrl":"https://doi.org/10.3121/cmr.2021.1718","url":null,"abstract":"<p><p><b>Objective:</b> Many clinical microbiology laboratories procure antimicrobial susceptibility testing data using guidelines established by Clinical and Laboratory Standards Institute (CLSI). When necessary, CLSI revises interpretive breakpoints in efforts to improve clinical correlation, with two revisions relative to fluoroquinolone agents occurring in 2019. The purpose of this investigation was to determine the impact of fluoroquinolone breakpoint revisions on Wisconsin clinical isolates of <i>Escherichia coli, Proteus mirabilis,</i> and <i>Pseudomonas aeruginosa.</i><b>Design:</b> Multi-center laboratory surveillance, with testing at a single location utilizing standardized media and susceptibility testing protocols.<b>Methods:</b> From the Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE) program, levofloxacin and ciprofloxacin minimum inhibitory concentration (MIC) values for 1911, 1521, and 1463 Wisconsin isolates of <i>E. coli, P. mirabilis,</i> and <i>P. aeruginosa,</i> respectively, were determined by broth microdilution testing. In separate data analyses, all MIC data were interpreted using CLSI breakpoints published prior to 2019, then secondarily by using CLSI breakpoints published since 2019 (which reflect lower breakpoints for both levofloxacin and ciprofloxacin resistance). Findings were further stratified by Wisconsin Department of Health Services region.<b>Results:</b> Up to 3.2% decreased statewide fluoroquinolone susceptibility was observed for <i>E. coli</i> isolates, while 5.1% and 6.3% decreases in levofloxacin susceptibility were noted for <i>P. aeruginosa</i> and <i>P. mirabilis</i> isolates, respectively, when revised breakpoints were applied. <i>E. coli</i> isolates from the Western region and <i>P. mirabilis</i> isolates from the Southeastern region demonstrated significant shifts toward decreased fluoroquinolone susceptibility upon application of revised breakpoints. Northern region <i>P. mirabilis</i> isolates exhibited consistently decreased fluoroquinolone susceptibility.<b>Conclusions:</b> Fluoroquinolone resistance has been underreported in Wisconsin as a whole, yet geographic variability continues to exist. Targeted annual surveillance is important to identify and monitor resistance trending. Compilations of SWOTARE surveillance data can be utilized to predict the impact of future CLSI interpretive breakpoint revisions in Wisconsin.</p>","PeriodicalId":47429,"journal":{"name":"Clinical Medicine & Research","volume":"20 2","pages":"81-88"},"PeriodicalIF":1.4,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242736/pdf/0200081.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39865034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Opioid Analgesia after Surgery: Assessing Postoperative Prescriptions from a Patient and Surgeon Perspective.","authors":"Roshini J Ramwani,&nbsp;Jessica A Wernberg","doi":"10.3121/cmr.2021.1630","DOIUrl":"https://doi.org/10.3121/cmr.2021.1630","url":null,"abstract":"<p><p><b>Purpose:</b> Nonmedical use of prescription opioids continues to be a public health crisis in the United States that disproportionately affects rural communities with diversion of pills from friends and family being the most common source. The primary goal of the study was to identify current opioid prescription practices, and to assess the discrepancy in amount of opioids prescribed by surgeons versus the amount needed post-operatively by patients. Patient factors that may influence postoperative analgesia needs and their management of leftover prescription opioids were also evaluated<b>Methods:</b> Patients ≥18 years-of-age who underwent a surgery between July and December 2018 by the subspecialty departments of Acute Care and General Surgery at a tertiary care facility in the rural Midwest were surveyed at their first post-operative visit to assess their postoperative analgesic needs. Resident and attending surgeons in the above departments were also surveyed to identify different factors that influenced their narcotic prescription practices.<b>Results:</b> Surveys from 252 patients, 12 attending surgeons, and 14 general surgery residents met inclusion criteria. Of patients who received a narcotic prescription, 19.9% did not fill their prescription, 64.1% of whom were >60 years old, and 72.1% resided within an hour of the hospital. Average reported prescription size was 11-40 pills; however, most used more than 5 pills regardless of the type of operation (<i>P</i>=0.59) and history of chronic pain (<i>P</i>=0.07). Inability to call in narcotic prescriptions and patients' distance from care influenced providers' prescription practices, with 77.9% of resident physicians and 68.3% of attending surgeons stating they would prescribe fewer if given the ability to call in a narcotic prescription.<b>Conclusions:</b> Regardless of the operation complexity, a majority of patients required fewer than five opioid pills after discharge and would be willing to return leftover pills. Development of opioid stewardship programs within the healthcare sector may reduce the number of opioids available for diversion and misuse.</p>","PeriodicalId":47429,"journal":{"name":"Clinical Medicine & Research","volume":"20 2","pages":"89-94"},"PeriodicalIF":1.4,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242732/pdf/0200089.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39865036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ketorolac and Predicted Severe Acute Pancreatitis: A Randomized, Controlled Clinical Trial.","authors":"Zahra Vahdat Shariatpanahi,&nbsp;Shaahin Shahbazi,&nbsp;Erfan Shahbazi","doi":"10.3121/cmr.2021.1663","DOIUrl":"https://doi.org/10.3121/cmr.2021.1663","url":null,"abstract":"<p><p><b>Objective:</b> We evaluated the effect of ketorolac on reducing the severity of acute pancreatitis.<b>Design and Setting:</b> Randomized clinical trial performed in a University hospital.<b>Participants:</b> There were 56 adult patients, with predicted severe acute pancreatitis, randomly divided into two groups.<b>Methods:</b> The patients in the study group received intravenous ketorolac, 10 mg, three times daily from the time of enrollment for a maximum of 5 days, as needed, along with standard medical treatment. Primary outcome measure was the change in the serum level of high sensitive C-reactive protein (hs-CRP). Patients were also followed up in terms of hospitalization duration, need for intensive care unit (ICU), organ failure development, persistent organ failure, pancreatic necrosis, nutritional assessment, and mortality. The study continued to gather clinical follow-up information up to 4 months.<b>Results:</b> Serum level of hs-CRP was significantly lower in the ketorolac group compared with the control group on days 3, 4, and 5. There were no significant differences in organ failure, pseudocyst formation, acute necrotic collection, mortality, and ICU transfer between groups. Days of hospitalization were significantly lower in the study group. The feeding start time was significantly shorter in the study group with no need for tube feeding in the ketorolac group. Frequency of NPO (not per oral) was significantly lower in the ketorolac group.<b>Conclusion:</b> The use of ketorolac may improve feeding outcomes and shorten length of hospitalization in predicted severe acute pancreatitis.</p>","PeriodicalId":47429,"journal":{"name":"Clinical Medicine & Research","volume":"20 2","pages":"74-80"},"PeriodicalIF":1.4,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242735/pdf/0200074.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39796792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}